Compare GAME & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAME | HOWL |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 46.7M |
| IPO Year | 2024 | 2021 |
| Metric | GAME | HOWL |
|---|---|---|
| Price | $2.48 | $0.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $11.33 | N/A |
| AVG Volume (30 Days) | 78.3K | ★ 322.8K |
| Earning Date | 11-16-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.14 | 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,999,302.00 | N/A |
| Revenue This Year | $91.12 | N/A |
| Revenue Next Year | $47.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.24 | $0.27 |
| 52 Week High | $3.85 | $1.20 |
| Indicator | GAME | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 47.43 |
| Support Level | $0.32 | $0.88 |
| Resistance Level | $2.84 | $0.99 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 39.71 | 17.33 |
GameSquare Holdings Inc is a vertically integrated digital media, entertainment, and technology company focused on gaming and youth culture audiences. The company operates through four reportable segments: Owned and Operated IP, Agency, SaaS and managed services, and Yield. It provides services including influencer marketing, esports talent management, creative production, merchandise and consumer products, live streaming analytics, and digital media solutions through its various brands and platforms. It generates the majority of its revenue from the Agency segment.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.